Navigation Links
Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
Date:10/5/2007

EMERYVILLE, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a leader in the discovery and development of safe and effective drugs in the areas of women's health and cancer, today announced that Tom Chesterman, SVP and CFO of Bionovo, Inc., will present at the 4th Annual BIO Investor Forum.

The presentation will take place on October 11, 2007 at 12:30 p.m. PDT at the Palace Hotel in San Francisco, CA.

A live audio web cast and slide presentation of the event will be available via a link at: http://www.bionovo.com.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the Nasdaq Capital Market under the symbol BNVI. For more information about Bionovo and its programs, visit http://www.bionovo.com.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...    Intrexon Corporation (NYSE: XON ... Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, ... exclusive strategic collaboration and license agreement to develop ... therapies. This collaboration advances Merck Serono,s comprehensive, science-driven ... immune system,s natural ability to fight tumors. ...
(Date:3/30/2015)... Washington, USA (PRWEB) March 29, 2015 ... and the United States and plenary talks by four ... SPIE Optics + Optoelectronics next month in ... technical presentations in 17 conferences alongside a two-day exhibition. ... and photonics , the event will run 13-16 April ...
(Date:3/30/2015)... N.J. , March 30, 2015  Naldemedine, ... under development by Shionogi & Co., Ltd., met ... III study (COMPOSE I) for the treatment of ... non-cancer pain receiving opioid therapy. Study results showed ... statistically significantly improved the frequency of spontaneous bowel ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015 ... (TSE: 4901) ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: ... ("CDI"), a leading developer and manufacturer of fully functioning ... announced that the two companies have entered into a ... all-cash tender offer to be followed by a second ...
Breaking Biology Technology:Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8
... 2, 2011 This September, during Prostate Cancer Awareness ... cancer screening method that may change the face of ... Cleveland hospitals and one Boston hospital, analyzed by the National ... urine screening. Dr. David Samadi, Vice Chairman, Department of ...
...  Sept. 2, 2011  PTC Therapeutics, Inc. and ... of their collaboration. Under the original agreement, PTC ... and Genzyme held commercial rights in all other ... rights to ataluren and Genzyme retains an option ...
... This release is available in German . ... and MIT professor Ron Weiss have successfully incorporated a ... recognizes certain cancer cells using logic combinations of five ... (Kobi) Benenson, Professor of Synthetic Biology at ETH Zurich, ...
Cached Biology Technology:More Precise Prostate Cancer Screening on Horizon 2More Precise Prostate Cancer Screening on Horizon 3PTC Therapeutics and Genzyme Announce Restructuring of Collaboration 2PTC Therapeutics and Genzyme Announce Restructuring of Collaboration 3Profiler at the cellular level 2Profiler at the cellular level 3
(Date:3/12/2015)... 2015 The mascots of the Atlantic Coast ... of Wake Forest Baptist Medical Center. They stopped by ... ACC Men,s Basketball Tournament. Young patients enjoyed bonding with ... their autographs. Brenner Children,s Hospital is the ... only children,s hospital in northwest North Carolina ...
(Date:3/11/2015)... --  The Sync Project™ today announced the ... harness music to improve health. The platform maps ... of physiology, enabling the study of the therapeutic ... It is designed for medical and health research, ... and accelerate the discovery of the clinical applications ...
(Date:3/10/2015)... Conn. , March 10, 2015  NXT-ID, ... ("NXT-ID" or the "Company"), a biometric authentication company ... the company,s Wocket™ smart wallet has been named ... by Rethink Modern. Rethink Modern ( ... and innovative items for your home and lifestyle that have ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... Reston, Va.SNM is calling on Congress to support the ... Radiation Therapy Act (CARE bill), which would ensure that ... medicine technologists. The bill (H.R. 3652) was introduced Sept. ... John Barrow (D-Ga.). "The introduction of ...
... The American Society of Agronomy (ASA) strongly supports ... to improve water quality in the Mississippi River Basin. ... voluntary, incentive-based program. "Clean water and profitable crop ... that have been developed by ASA members. The initiative ...
... to develop as two of the most exciting areas ... public is almost completely unaware of the science and ... conducted by Peter D. Hart Research Associates and the ... of Americans think the public should be better informed ...
Cached Biology News:SNM urges Congress to support CARE bill 2Agronomy Society welcomes USDA Mississippi River Basin Initiative 2Nanotechnology and synthetic biology: What does the American public think? 2
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Raised to arginine vasopressin coupled to bovine thyroglobulin with carbodiimide ....
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Biology Products: